Is CHILLS a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed CHILLS.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 40 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported CHILLS to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and CHILLS. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause CHILLS, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes CHILLS. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if CHILLS ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing CHILLS: 40
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where CHILLS is a reported side effect: 1.2016%

FDA reports of any drug causing CHILLS : 33540
Average percentage for all medicated patients where CHILLS is reported as a complication: 0.2102%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with CHILLS:

ASPIRIN (2154 patients)
REMICADE (2099 patients)
HEPARIN SODIUM INJECTION (1818 patients)
HUMIRA (1793 patients)
AVONEX (1709 patients)
PREDNISONE (1327 patients)
ENBREL (1245 patients)
METHOTREXATE (1047 patients)
NEXIUM (980 patients)
ZOMETA (975 patients)
ACETAMINOPHEN (964 patients)
SYNTHROID (928 patients)
LIPITOR (895 patients)
FOSAMAX (878 patients)
FOLIC ACID (872 patients)
TYSABRI (864 patients)
LISINOPRIL (806 patients)
OMEPRAZOLE (796 patients)
REBIF (772 patients)
LASIX (772 patients)
OXYCONTIN (748 patients)
VITAMIN D (722 patients)
PRILOSEC (715 patients)
ATENOLOL (702 patients)
SANDOSTATIN LAR (701 patients)
BENADRYL (688 patients)
BYETTA (664 patients)
GAMMAGARD LIQUID (657 patients)
BETASERON (653 patients)
PREDNISOLONE (647 patients)
NEURONTIN (646 patients)
AMBIEN (642 patients)
XANAX (640 patients)
SIMVASTATIN (637 patients)
PEGASYS (633 patients)
IBUPROFEN (626 patients)
PAXIL (606 patients)
ZOFRAN (600 patients)
COUMADIN (588 patients)
CYMBALTA (587 patients)
HYDROCHLOROTHIAZIDE (580 patients)
NORVASC (580 patients)
SEROQUEL (575 patients)
PROTONIX (573 patients)
PLAVIX (565 patients)
PREDNISONE TAB (562 patients)
ATIVAN (555 patients)
ALBUTEROL (553 patients)
DEXAMETHASONE (553 patients)
LEVOTHYROXINE SODIUM (548 patients)
LYRICA (547 patients)
RIBAVIRIN (544 patients)
POTASSIUM CHLORIDE (529 patients)
ALLOPURINOL (526 patients)
FUROSEMIDE (514 patients)
DURAGESIC-100 (512 patients)
VIOXX (511 patients)
CALCIUM (499 patients)
RECLAST (498 patients)
LEVAQUIN (491 patients)
ZOLOFT (489 patients)
LORAZEPAM (488 patients)
FORTEO (486 patients)
VICODIN (481 patients)
CYCLOPHOSPHAMIDE (472 patients)
METFORMIN HCL (471 patients)
CELEBREX (459 patients)
GABAPENTIN (451 patients)
PERCOCET (449 patients)
PREVACID (439 patients)
ZOCOR (430 patients)
LEXAPRO (429 patients)
TOPROL-XL (427 patients)
DECADRON (419 patients)
TYLENOL (409 patients)
FLUOROURACIL (407 patients)
CRESTOR (405 patients)
CARBOPLATIN (404 patients)
HEPARIN SODIUM (400 patients)
CLONAZEPAM (400 patients)
OXYCODONE HCL (399 patients)
MULTI-VITAMINS (397 patients)
EXTAVIA (392 patients)
METOPROLOL TARTRATE (392 patients)
FABRAZYME (391 patients)
ACCUTANE (379 patients)
MORPHINE (378 patients)
DIOVAN (365 patients)
VANCOMYCIN (365 patients)
AREDIA (363 patients)
SOLIRIS (359 patients)
PREMARIN (357 patients)
DIGOXIN (357 patients)
TYLENOL (CAPLET) (352 patients)
CHANTIX (351 patients)
SINGULAIR (350 patients)
ADVAIR DISKUS 100/50 (345 patients)
EFFEXOR (344 patients)
EXJADE (340 patients)
KLONOPIN (335 patients)
LANTUS (334 patients)
NIASPAN (334 patients)
PEG-INTRON (328 patients)
ACYCLOVIR (324 patients)
FENTANYL (323 patients)
MULTI-VITAMIN (322 patients)
PROZAC (321 patients)
CELEXA (319 patients)
AMLODIPINE (319 patients)
CISPLATIN (318 patients)
BACTRIM (315 patients)
REVLIMID (311 patients)
VALIUM (305 patients)
COMPAZINE (300 patients)
DIAZEPAM (298 patients)
ZYRTEC (294 patients)
VELCADE (294 patients)
ZANTAC (292 patients)
ACTONEL (289 patients)
ZITHROMAX (286 patients)
TRAMADOL HCL (285 patients)
COPEGUS (285 patients)
INSULIN (284 patients)
LORTAB (278 patients)
WARFARIN SODIUM (277 patients)
ALLEGRA (274 patients)
AVASTIN (273 patients)
FLUCONAZOLE (272 patients)
PROPOFOL (272 patients)
BONIVA (272 patients)
RITUXIMAB (271 patients)
PANTOPRAZOLE (265 patients)
LAMICTAL (260 patients)
TRAZODONE HCL (260 patients)
ACLASTA (259 patients)
TAXOTERE (258 patients)
CIPROFLOXACIN (258 patients)
RADIATION THERAPY (257 patients)
WELLBUTRIN (256 patients)
TAXOL (256 patients)
CALCIUM CARBONATE (256 patients)
FLEXERIL (255 patients)
ALPRAZOLAM (253 patients)
FISH OIL (250 patients)
EFFEXOR XR (248 patients)
ARANESP (247 patients)
AUGMENTIN '125' (246 patients)
NITROGLYCERIN (246 patients)
ASCORBIC ACID (245 patients)
FLOMAX (244 patients)
BACLOFEN (243 patients)
COREG (243 patients)
GLUCOPHAGE (242 patients)
MYLOTARG (242 patients)
RITUXAN (242 patients)
SPIRIVA (240 patients)
AVELOX (240 patients)
METOPROLOL (237 patients)
THYMOGLOBULIN (236 patients)
DOXORUBICIN HCL (232 patients)
FLAGYL (229 patients)
ERBITUX (228 patients)
SOLU-MEDROL (227 patients)
COZAAR (227 patients)
AMOXICILLIN (226 patients)
INCIVEK (224 patients)
DILAUDID (222 patients)
PEPCID (219 patients)
GLIPIZIDE (218 patients)
REGLAN (217 patients)
IRON (216 patients)
GLYBURIDE (215 patients)
OXALIPLATIN (214 patients)
NEUPOGEN (214 patients)
METFORMIN (212 patients)
LANSOPRAZOLE (211 patients)
RANITIDINE (211 patients)
AMITRIPTYLINE HCL (210 patients)
VITAMIN B-12 (209 patients)
VOLTAREN (209 patients)
ZOLEDRONOC ACID (207 patients)
COLACE (205 patients)
LOVENOX (204 patients)
ENALAPRIL MALEATE (203 patients)
CLONIDINE (202 patients)
CYTARABINE (200 patients)
CYCLOSPORINE (200 patients)
ACTOS (200 patients)
MORPHINE SULFATE (197 patients)
HYDROCORTISONE (197 patients)
DIFLUCAN (197 patients)
RAMIPRIL (196 patients)
NAPROXEN (196 patients)
CIPRO (196 patients)
GILENYA (195 patients)
PROCRIT (194 patients)
MIRALAX (194 patients)
VINCRISTINE (193 patients)
FLONASE (192 patients)
HERCEPTIN (192 patients)
LEVOXYL (192 patients)
HEPARIN (189 patients)
LEUCOVORIN CALCIUM (189 patients)
PACLITAXEL (187 patients)
PLAQUENIL (186 patients)
MOBIC (184 patients)
GLEEVEC (184 patients)
ETOPOSIDE (183 patients)
MS CONTIN (183 patients)
MABTHERA (182 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about CHILLS and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.